Slide Striving to unleash the potential of mTOR inhibition using precision medicine and nanoparticle albumin technology At Aadi Bioscience, our mission is to improve the lives of people with mTOR-driven diseases. We believe success depends on addressing the limitations of current mTOR inhibitors and leveraging the latest genomic profiling technology to identify the patients most likely to benefit from mTOR inhibition.

Our Approach:

Identify diseases with mTOR pathway genomic alterations and strong evidence of mTOR involvement in pathology of disease

Target genomically defined subgroups across cancer types with mTOR pathway alterations (e.g., TSC1, TSC2) who are most likely to respond to mTOR treatment

Investigate and develop albumin-bound nanoparticle therapies for appropriate patient populations